Navigation Links
OncoGenex Technologies Announces Phase II Data of OGX-011 in,Metastatic Breast Cancer at American Association for Cancer,Research 2007 Annual Meeting

VANCOUVER, April 17, 2007 /PRNewswire/ - OncoGenex Technologies Inc. announced today data from a Phase II clinical trial of OGX-011 in combination with docetaxel in patients with metastatic breast cancer (MBC). Data was presented by the National Cancer Institute of Canada - Clinical Trials Group at the American Association for Cancer Research 2007 Annual Meeting in Los Angeles, Calif.

    Investigators concluded:

        -  Of the 15 patients treated, five patients (33.3 percent) showed a

           partial response and nine patients (60 percent) showed disease

           stabilization

        -  Of the nine patients reported with stable disease, tumor reduction

           ranged from approximately eight to 28 percent and disease

           stabilization was sustained for a median of 9.3 months

        -  Only one patient advanced to progressive disease

        -  While patient monitoring is ongoing, the median progression free

           survival for all patients was eight months and the median time for

           survival has not yet been reached

        -  Clinical activity was seen for the combination of OGX-011 and

           docetaxel in this generally pre-treated group of patients with

           MBC, but did not meet the pre-determined criteria of six or more

           patients achieving tumour size reductions exceeding 30 percent

           required to expand the trial into a second stage of accrual

        -  Serum clusterin levels fell on treatment in most patients, and

           there was no statistical correlation between changes from baseline

           in clusterin levels and objective tumor response

"Taxanes represent an active class of chemotherapeutic agents currently used in the treatment of breast cancer, however the majority of patients will eventually develop resistance to the therapies," said Dr. Stephen Chia, Principal Investigator for this study
'"/>




Page: 1 2 3 4

Related medicine technology :

1. OncoGenex and Isis Announce OGX-011 Data to be Presented at ASCO
2. Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
3. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
4. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
5. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
6. Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 20th International Conference on Antiviral Research Meeting
7. Micell Technologies Presents Data on Novel Drug-Eluting Stents
8. AVAX Technologies Presents Results of Phase I-II M-Vax Trial at Annual Meeting of American Association for Cancer Research
9. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:9/15/2014)... , Sept. 15, 2014  Valeant Pharmaceuticals International, Inc. ... its wholly owned subsidiary, Valeant Pharmaceuticals International, will redeem ... of its 6.75% Senior Notes due 2017, CUSIP Nos. ... 2014 and has mailed an irrevocable notice of redemption ... a copy of the irrevocable notice of redemption with ...
(Date:9/15/2014)... TAMPA, Fla. , Sept. 15, 2014 ... Dr. Steven Stanos with an expanded role ... program. Dr. Stanos, a nationally recognized physiatrist ... on topics related to rehabilitation and workers, compensation, is ... medicine by the American Board of Pain Medicine and ...
(Date:9/15/2014)... PDL BioPharma, Inc. (PDL) (NASDAQ: ... September 12, 2014, regular quarterly dividend payment of $0.15 per ... of September 5, 2014, the record date. ... portfolio of patents and royalty assets, consisting primarily of ... agreements with various biotechnology and pharmaceutical companies. PDL pioneered ...
Breaking Medicine Technology:Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 2myMatrixx Announces Expanded Role for Medical Director Steven P. Stanos, Jr., DO 2PDL BioPharma Completes Regular Quarterly Dividend Payment 2
... NJ, Aug. 18 /PRNewswire-Asia/ -- ... ... var shortURL = ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... On August 9, 2010 Massachusetts passed Chapter 283 ... Prescription Monitoring Program and furthering Substance Abuse Education and ... in Massachusetts that dispense schedule II, III, IV, or ... sale at each location. More info at http://www.mass.gov/legis/laws/seslaw10/sl100283.htm ...
Cached Medicine Technology:Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 2Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 3Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 4Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 5Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 6New Law Requires Pharmacies in Massachusetts to Carry Rx Lock Boxes 2
(Date:9/16/2014)... Hills, CA (PRWEB) September 16, 2014 ... announce the launch of ACLsurgeryLA.com , a specialty ... ACL injuries. As an avid sports lover and ... options for treatment and recovery from injuries to maintain ... opportunity to offer patients a resource dedicated specifically to ...
(Date:9/16/2014)... NY (PRWEB) September 16, 2014 Registration ... Run For The Warriors®, a 10K, 5K, and 1-mile ... The race is sponsored by Local 338 RWDSU/UFCW, the ... will begin at the Town of Babylon Town Hall ... http://www.hopeforthewarriors.org/2014LIRun . The run is organized by Hope ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 *To find out ... visit Achieve Clinical Research on the web ( http://www.achieveclinical.com/trial/pneumonia-vaccine/ ) ... who qualify:, There is no cost ... , Compensation may be provided for time and ... and influenza are the eighth leading cause of death in ...
(Date:9/16/2014)... DeLand, Florida (PRWEB) September 16, 2014 ... clinical trials being conducted in DeLand, FL can visit ... or contact them directly at (386) 785-2404. , Why ... of the most widespread viral diseases infecting mankind. While ... past, these colds still account for more annual visits ...
(Date:9/16/2014)... 2014 justthoughtyoushouldknow.org , popular ... launches their new site today. The new site ... at making information easier to find, ingest, and ... into one-page, easy-to-read pages the information that we ... Virginia Downie, retired college professor and founder of ...
Breaking Medicine News(10 mins):Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 3Health News:The Hope For The Warriors Long Island Run For The Warriors to Honor Wounded and Families of the Fallen 2Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 2Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 3Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 2Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 3Health News:JustThoughtYouShouldKnow.org Debuts New Website 2
... Dec. 6 Arete Therapeutics Inc., a,privately-held biopharmaceutical ... of cardiovascular, inflammatory and,metabolic diseases, today announced the ... directors., "We are very pleased to welcome ... and operational insights will be of great benefit ...
... Name Also Unveiled in Ongoing Preparation for ... Favrille, Inc. (Nasdaq:,FVRL), a biopharmaceutical company ... cancer, announced that new data,including four-year follow-up ... of Specifid(TM) (formerly FavId(R)), will be reported ...
... Oncology, the nation,s leading,oncology services company, today named ... and chief operating officer. The appointment,becomes effective on ... experience, combined with his work in,large diversified healthcare ... Broussard, president of US Oncology.,"His proven success in ...
... first increase in U.S.,teen pregnancy rates, WASHINGTON, Dec. ... pregnancy rates in the United States over the,last fourteen ... should not come as a surprise since the dual ... -- the decline in sexual,initiation and more effective use ...
... http://feeds.feedburner.com/OrthoWomensHealthAndUrology , RARITAN, NJ, December 5 Jane ... about the Pill as part of The Modern,Girl,s Guide ... Girl,s Guide to the Pill, When: The Podcast ... Where: http://feeds.feedburner.com/OrthoWomensHealthAndUrology , How: Go to ...
... With the popularity of,fillers becoming mainstream, it,s no ... prevent facial wrinkles. Dr. Arnold Klein, world,renowned cosmetic ... "Fillers such as Artefill, Radiesse and Sculptra contain ... tissue, all of,these products can cause foreign body ...
Cached Medicine News:Health News:Arete Therapeutics Appoints Donald Santel to Board of Directors 2Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 2Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 3Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 4Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 5Health News:US Oncology Appoints Glen Laschober EVP & Chief Operating Officer 2Health News:Facial Deformity Danger? 2
...
Adjustable wire speculum with 17 mm open blades. Lid tension adjustable throughout procedure with thumb screw control. Shaft angled 45 degrees. Manufactured in titanium....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Open 15 mm blades with lifting wings manipulation of I/A cannulas, knives, instrumentation, etc. Screwlocking mechanism. Dull finish....
Medicine Products: